Patents by Inventor Mattheus Cornelis de Wilde
Mattheus Cornelis de Wilde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918546Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereofType: GrantFiled: August 11, 2021Date of Patent: March 5, 2024Assignee: N.V. NutriciaInventor: Mattheus Cornelis de Wilde
-
Publication number: 20210386682Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereofType: ApplicationFiled: August 11, 2021Publication date: December 16, 2021Applicant: N.V. NutriciaInventor: Mattheus Cornelis de Wilde
-
Patent number: 11123306Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.Type: GrantFiled: March 8, 2017Date of Patent: September 21, 2021Assignee: N.V. NutriciaInventor: Mattheus Cornelis De Wilde
-
Publication number: 20200261488Abstract: The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the subject a composition comprising therapeutically effective amounts of: (i) one or more of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), preferably at least DHA, more preferably DHA and EPA, wherein the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.Type: ApplicationFiled: January 10, 2020Publication date: August 20, 2020Inventors: Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman
-
Patent number: 10632093Abstract: The invention pertains to the use of a composition in the manufacture of a product or method for therapeutically improving, promoting, restoring or maintaining recognition and/or working memory in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired recognition and/or working memory associated with PKU, said composition comprising therapeutic amounts of: (i) at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) choline, a choline salt and/or choline ester; and (iii) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, including functional equivalents thereof, preferably vitamin B6 and/or vitamin B12, and functional equivalents thereof. The invention also pertains to a composition for use in such use or method.Type: GrantFiled: October 24, 2016Date of Patent: April 28, 2020Assignee: N.V. NUTRICIAInventors: Mattheus Cornelis De Wilde, Danielle Stefanie Counotte
-
Publication number: 20190076375Abstract: The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and/or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and/or slowing down brain atrophy in a human subject in need thereof.Type: ApplicationFiled: March 8, 2017Publication date: March 14, 2019Applicant: N.V. NUTRICIAInventor: Mattheus Cornelis DE WILDE
-
Publication number: 20190070126Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.Type: ApplicationFiled: March 8, 2017Publication date: March 7, 2019Applicant: N.V. NUTRICIAInventor: Mattheus Cornelis DE WILDE
-
Publication number: 20180311197Abstract: The invention pertains to the use of a composition in the manufacture of a product or method for therapeutically improving, promoting, restoring or maintaining recognition and/or working memory in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired recognition and/or working memory associated with PKU, said composition comprising therapeutic amounts of: (i) at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) choline, a choline salt and/or choline ester; and (iii) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, including functional equivalents thereof, preferably vitamin B6 and/or vitamin B12, and functional equivalents thereof. The invention also pertains to a composition for use in such use or method.Type: ApplicationFiled: October 24, 2016Publication date: November 1, 2018Applicant: N.V. NutriciaInventors: Mattheus Cornelis DE WILDE, Danielle Stefanie COUNOTTE
-
Publication number: 20180311196Abstract: The invention pertains to the use of a composition in the manufacture of a productor method for therapeutically improving, promoting, restoring or maintaining white matter integrity in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired white matter integrity associated with PKU, said composition comprising therapeutic amounts of at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); and one of more of uridine, cytidine and/or an equivalent thereof, including salts, phosphates, acyl derivatives and/or esters. The invention also pertains to a composition for use in such use or method.Type: ApplicationFiled: October 24, 2016Publication date: November 1, 2018Applicant: N.V. NutriciaInventors: Paul Johannes Maria SAVELKOUL, Jan Maarten VERKUIJL, Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE, Danielle Stefanie COUNOTTE, Maryam RAKHSHANDEHROO
-
Publication number: 20180280332Abstract: The invention pertains to a method for improving or promoting equilibrioception or coordination and balance in a healthy subject, comprising administration of: (i) ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) one of more of uridine, cytidine and/or an equivalent thereof, including salts, phosphates, acyl derivatives and/or esters; and (iii) free leucine, to said healthy subject. The invention also pertains to a composition for use in such a method.Type: ApplicationFiled: October 24, 2016Publication date: October 4, 2018Applicant: N.V. NutriciaInventors: Mattheus Cornelis DE WILDE, Danielle Stefanie COUNOTTE
-
Patent number: 10071072Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.Type: GrantFiled: January 27, 2017Date of Patent: September 11, 2018Assignee: N.V. NUTRICIAInventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Sijben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
-
Patent number: 9968629Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 ?M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.Type: GrantFiled: August 13, 2013Date of Patent: May 15, 2018Assignee: N.V. NutriciaInventors: Martine Groenendijk, Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde
-
Publication number: 20180110794Abstract: The invention pertains to the use of uridine and/or an equivalent thereof and n3-PUFA in the manufacture of a product for restoring or improving bladder function in a subject, in particular in a patient suffering from spinal cord injury.Type: ApplicationFiled: March 15, 2016Publication date: April 26, 2018Applicant: N.V. NutriciaInventor: Mattheus Cornelis DE WILDE
-
Publication number: 20170157163Abstract: The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof in the manufacture of a composition for use in a method for treating, stabilizing or slowing down brain glucose metabolism deficit in a subject in need thereof.Type: ApplicationFiled: February 2, 2015Publication date: June 8, 2017Applicant: N.V. NutriciaInventors: Maria Ladislaus BROERSEN, Robert Johan Joseph HAGEMAN, Marieke LANSBERGEN, Martine GROENENDIJK, Mattheus Cornelis DE WILDE
-
Publication number: 20170135975Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.Type: ApplicationFiled: January 27, 2017Publication date: May 18, 2017Applicant: N.V. NutriciaInventors: Mattheus Cornelis DE WILDE, Johannes Wilhelmus Christina SIJBEN, Patrick Joseph Gerardus Hendrikus KAMPHUIS, Robert Johan Joseph HAGEMAN
-
Patent number: 9585900Abstract: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.Type: GrantFiled: June 30, 2015Date of Patent: March 7, 2017Assignee: N. V. NutriciaInventors: Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Patent number: 9579336Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.Type: GrantFiled: March 14, 2012Date of Patent: February 28, 2017Assignee: N.V. NutriciaInventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Sijben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
-
Patent number: 9446014Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: GrantFiled: July 2, 2013Date of Patent: September 20, 2016Assignee: N. V. NutriciaInventors: Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20150327586Abstract: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.Type: ApplicationFiled: June 30, 2015Publication date: November 19, 2015Inventors: Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman, Martine Grornrnfijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20150297622Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 ?M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.Type: ApplicationFiled: August 13, 2013Publication date: October 22, 2015Applicant: N.V. NutriciaInventors: Martine GROENENDIJK, Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE